Paul Gross, MD
Psychiatry · Allentown, PANPI 1598871097
Payments from drug & device makers
Across 835 payments — averaging $4941.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$889K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$649K
- Biogen$611K
- Janssen Research & Development, LLC$582K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$561K
- Teva Pharmaceuticals USA, Inc.$192K
- plus $642K from 21 others
Across 2 payments — averaging $6391.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$13K
What the payments were for
- Food & beverage$981100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 210 | $888,789 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 13 | $649,250 |
| Biogen | 9 | $610,598 |
| Janssen Research & Development, LLC | 141 | $582,116 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 88 | $560,561 |
| Teva Pharmaceuticals USA, Inc. | 46 | $192,433 |
| Eli Lilly | 10 | $188,957 |
| Sumitomo Pharma America, Inc. | 118 | $158,886 |
| Sage Therapeutics, LLC | 28 | $82,153 |
| Sunovion Pharmaceuticals Inc. | 62 | $70,819 |
| Boehringer Ingelheim | 5 | $32,113 |
| Alkermes, Inc. | 37 | $31,150 |
| Biohaven Pharmaceuticals, Inc. | 9 | $22,289 |
| Swing Therapeutics, Inc. | 10 | $13,728 |
| E.r. Squibb & Sons, L.L.C. | 2 | $11,622 |
| Genentech, Inc. | 4 | $10,535 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $9,922 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 17 | $6,506 |
| Boehringer Ingelheim International GmbH | 1 | $3,170 |
| Johnson & Johnson | 11 | $202 |
| Merck | 1 | $54 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $43 |
| Lundbeck LLC | 2 | $28 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
| Neuronetics, Inc. | 1 | $10 |
How this compares
$4,126,015 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 20 | $32,053 |
| RexultiBrexpiprazole | 24 | $31,440 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $11,944 |
| TrintellixVortioxetine Hydrobromide | 16 | $9,200 |
| Aripiprazole | 185 | $8,104 |
| Clomipramine Hcl | 19 | $7,798 |
| Lurasidone Hcl | 17 | $7,490 |
| Asenapine Maleate | 18 | $6,714 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 280 | $5,208 |
| Quetiapine Fumarate | 204 | $4,374 |
| Duloxetine Hcl | 191 | $4,115 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 87 | $3,640 |
| Trazodone Hcl | 303 | $3,535 |
| Lorazepam | 405 | $3,489 |
| Carbamazepine ErCarbamazepine | 19 | $3,007 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $560,561 | $32,05320 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $44 | $31,44024 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $43 | $9,20016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Allentown
- Cherian VergheseNorristown$16.3M
- Steven ArnoldPhiladelphia$4.1M
- Shivkumar HattiMedia$4M
- Rebecca RomaPittsburgh$3.3M
- Matthew BergerMoosic$2.4M
- Michael ThasePhiladelphia$2.2M
- Robert NelsonWyomissing$2.2M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
- Daniel WeintraubPhiladelphia$647K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.